Literature DB >> 9462744

Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.

D Martindale1, A Hackam, A Wieczorek, L Ellerby, C Wellington, K McCutcheon, R Singaraja, P Kazemi-Esfarjani, R Devon, S U Kim, D E Bredesen, F Tufaro, M R Hayden.   

Abstract

It is unclear how polyglutamine expansion is associated with the pathogenesis of Huntington disease (HD). Here, we provide evidence that polyglutamine expansion leads to the formation of large intracellular aggregates in vitro and in vivo. In vitro these huntingtin-containing aggregates disrupt normal cellular architecture and increase in frequency with polyglutamine length. Huntingtin truncated at nucleotide 1955, close to the caspase-3 cleavage site, forms perinuclear aggregates more readily than full-length huntingtin and increases the susceptibility of cells to death following apoptotic stimuli. Further truncation of huntingtin to nucleotide 436 results in both intranuclear and perinuclear aggregates. For a given protein size, increasing polyglutamine length is associated with increased cellular toxicity. Asymptomatic transgenic mice expressing full-length huntingtin with 138 polyglutamines form exclusively perinuclear aggregates in neurons. These data support the hypothesis that proteolytic cleavage of mutant huntingtin leads to the development of aggregates which compromise cell viability, and that their localization is influenced by protein length.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462744     DOI: 10.1038/ng0298-150

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  121 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 2.  Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

Authors:  A Lunkes; Y Trottier; J Fagart; P Schultz; G Zeder-Lutz; D Moras; J L Mandel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Authors:  A S Hackam; J G Hodgson; R Singaraja; T Zhang; L Gan; C A Gutekunst; S M Hersch; M R Hayden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

5.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

6.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 7.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

8.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

9.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.

Authors:  S Waelter; A Boeddrich; R Lurz; E Scherzinger; G Lueder; H Lehrach; E E Wanker
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 10.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.